Summary

Cancer cells are quick to develop resistance to anti-tumor drugs. New research by scientists from the University of California, Davis, shows how cancers adapt to evade a class of anti-tumor drugs called BET inhibitors and offers hope for more effective therapies. The researchers showed that when BET inhibitors eliminate their target protein, BRD4, cancer cells compensate by increasing the production of a related protein called BRD2, which takes over BRD4's epigenetic functions and allows the tumor to survive and grow.

AI summaries can be wrong sometimes—always verify important details using the source article.